Samsrita Labs Ltd

Samsrita Labs Limited's Board of Directors met on September 28, 2026, approving several material related party transactions with S Labs Hygiene Care Private Limited. These include an investment of up to ₹1 Crore in Compulsory Convertible Preference Shares (CCPS) and sale transactions up to ₹25 Crores. The board also approved availing an unsecured working capital loan of up to ₹1 Crore from Mr. Ravikanth Naga Pattabhi Chopperla, a Non-Executive Director. All these transactions are subject to shareholder approval. Additionally, the company scheduled its Extra-Ordinary General Meeting for FY 2026-27 for October 26, 2026.

Samsrita Labs Ltd has announced the closure of its trading window for dealing in the company's securities. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct. The trading window will be shut from October 1, 2026, until 48 hours after the declaration of standalone and consolidated un-audited financial results for the quarter and half-year ending September 30, 2026. This restriction applies to all designated persons, their immediate relatives, and connected persons. The company will separately intimate the stock exchanges regarding the board meeting scheduled to approve these financial results.

Samsrita Labs Ltd has filed a statement confirming no deviation or variation in the utilization of funds raised through a preferential issue for the quarter ended June 30, 2026. The funds were raised on July 18, 2025, amounting to ₹339.10 lakhs. The utilization for working capital, investment in new projects, repayment of unsecured loans, and general corporate purposes remained as originally allocated, with zero deviation reported for the quarter. The Audit Committee reviewed and approved the statement.

Samsrita Labs Limited announced that its Board of Directors met on August 13, 2026, to consider and approve the un-audited standalone and consolidated financial results for the quarter ended June 30, 2026. The board also approved the Limited Review Reports from the statutory auditors for the same period. The meeting commenced at 3:30 p.m. and concluded at 4:00 p.m. The company operates in the Health Care Sector.

Samsrita Labs Limited announced its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The Board of Directors approved these results along with the Limited Review Reports from the statutory auditors. The meeting was held on August 13, 2026. The company operates in the Health Care Sector and has only one reportable segment.

Samsrita Labs Ltd has announced that its Board of Directors will convene on August 13, 2026, to consider and approve the un-audited financial results for the quarter ended June 30, 2026. The meeting will also include a review of the Limited Review Report from the statutory auditor. The board meeting is scheduled to commence at 3:30 PM at the company's registered office in Hyderabad.

Samsrita Labs Ltd has announced the schedule for its 30th Annual General Meeting (AGM) for the Financial Year 2025-26. The AGM will be held on Monday, August 10, 2026, at 11:00 AM IST, conducted entirely through Video Conferencing (VC) and Other Audio-Visual Means (OAVM). The company has also submitted the Notice of AGM and the Annual Report for FY 2025-26, in compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The cut-off date for determining eligibility to attend the AGM is Monday, August 3, 2026. The filing includes details of the company's board of directors, committees, auditors, and financial statements.

Samsrita Labs Ltd has submitted the Notice of its 30th Annual General Meeting (AGM) and the Annual Report for the Financial Year 2025-26. The AGM is scheduled for Monday, August 10, 2026, at 11:00 AM IST, to be conducted via Video Conferencing (VC) / Other Audio-Visual Means (OAVM). The cut-off date for determining eligibility to attend the AGM is Monday, August 03, 2026. The filing includes comprehensive details such as the Board of Directors, Corporate Information, financial statements, auditor reports, and management discussion and analysis.

Samsrita Labs Ltd announced the outcome of its board meeting held on July 4, 2026. The board approved a scheme of capital reduction involving the cancellation and extinguishment of 1,13,74,855 equity shares. This move aims to realign and reorganize the company's equity capital structure, set off past accumulated losses, and improve the net worth. The reduction will decrease the paid-up equity share capital and cancel the entire share premium amount. No benefit will accrue to the promoter or promoter group from this restructuring. The shareholding pattern will be adjusted to maintain existing percentage holdings.

Samsrita Labs Ltd announced the outcome of its Board Meeting held on July 4, 2026. Key decisions included the appointment of Mr. Ravi Kanth Naga Pattabhi Chopperla as an Additional Director (Professional & Non-Executive) and Mr. Satyanarayana Murthy Varanasi as an Additional Director (Independent). The Board also approved a Scheme of Reduction of Capital, subject to shareholder and NCLT approvals. Additionally, the company will alter its Memorandum of Association to include pet animal healthcare services, enter into related party transactions with QROPS Advisory Services Private Limited, and finalized the Directors' Report and AGM notice for FY 2025-26. The AGM is scheduled for August 10, 2026.